Quantum BioPharma Ltd. (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary multiple sclerosis therapy candidate, LUCID-MS, which targets demyelination and aims to protect or restore myelin integrity. The company reported that Phase 1 clinical studies in healthy volunteers demonstrated a favorable safety profile and that the therapy was generally well tolerated, supporting advancement into patient-focused studies. In April 2026, Quantum BioPharma submitted an Investigational New Drug application to the U.S. Food and Drug Administration for LUCID-MS, paving the way for a planned Phase 2 clinical trial in people living with multiple sclerosis.
The company believes the therapy may offer a differentiated, potentially first-in-class approach because it aims to directly address myelin loss and neurodegeneration, rather than relying solely on immune modulation. This mechanism could represent a significant shift in treating multiple sclerosis, a chronic autoimmune disease affecting the central nervous system. Quantum BioPharma is strengthening operational support for the program through a planned partnership with Allucent and engagement with neurological specialists, as noted in a recent article highlighting the company’s progress (https://ibn.fm/AUhNl).
Quantum BioPharma is a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders and alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., Quantum BioPharma is focused on the research and development of its lead compound, Lucid-MS. Lucid-MS is a patented new chemical entity shown to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company also invented unbuzzd and spun out its OTC version to Unbuzzd Wellness Inc., retaining a 19.84% ownership stake (as of March 31, 2026) and royalty payments of 7% of sales until $250 million is reached, after which the royalty drops to 3% in perpetuity. Quantum BioPharma retains 100% of the rights to develop similar products or alternative formulations specifically for pharmaceutical and medical uses.
The progression of LUCID-MS into Phase 2 trials is a critical milestone for the company and for patients with multiple sclerosis, who currently have limited treatment options that primarily focus on immune modulation. If successful, LUCID-MS could offer a disease-modifying therapy that directly repairs myelin, potentially slowing or reversing disability progression. Investors can find the latest news and updates relating to QNTM in the company’s newsroom (https://ibn.fm/QNTM). This development underscores Quantum BioPharma’s commitment to addressing unmet medical needs in neurodegenerative diseases.
